Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE Celera Genomics Signs Contract with Univ. of Tokyo on Genome Database
January 22, 2001
-
ARCHIVE Daiichi Forms Alliance with MedGene
January 22, 2001
-
ARCHIVE R&D Investment by 9 Major Companies Increases 3.5% in First 6 Months
January 22, 2001
-
ARCHIVE SCRIP Tokyo Office Moves
January 22, 2001
-
ARCHIVE Daiichi Pure Chemicals Starts Contract SNP Analysis Services
January 22, 2001
-
ARCHIVE Merger with Mitsui Pharm Strengthens Schering Group's Product Line
January 22, 2001
-
ARCHIVE 15 Researchers Win AstraZeneca Asthma Research Award
January 22, 2001
-
ARCHIVE Cancer to Be Next 'Franchise' Area Following CNS, GI Fields: Mr Shinoda of Eisai
January 22, 2001
-
ARCHIVE New Kosei-Rodosho Inaugurated on Jan. 6
January 22, 2001
-
ARCHIVE Kyushu Univ. Opens Master's Course to Train Specialized Medical Professionals
January 22, 2001
-
ARCHIVE National Organization Proposed to Train CRCs: Kyoto Univ. Seminar
January 22, 2001
-
ARCHIVE Kosei-Rodosho Wants to Settle All Drug Price Issues in 2002 Reform
January 22, 2001
-
ARCHIVE Ain Pharmaciez to Become No. 1 Dispensing Pharmacy Operator: Report
January 22, 2001
-
ARCHIVE SBS, GSK Copromote Antidepressant
January 22, 2001
-
ARCHIVE Revised GPMSP to Be Enforced from October 1
January 22, 2001
-
ARCHIVE OTC NEWS IN BRIEF
January 22, 2001
-
ARCHIVE Santen Markets Betimol for Glaucoma in the US
January 22, 2001
-
ARCHIVE LDP Hashimoto Group Proposes Copayment of 10% or More for Elderly Healthcare
January 22, 2001
-
ARCHIVE DIAGNOSTIC NEWS IN BRIEF
January 22, 2001
-
ARCHIVE Life Science Units of Tomen, Nichimen to Merge into New Company
January 22, 2001
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…